South San Francisco, Calif.
Went public 5/2/2000 at $7 a piece
Filing Range: 5 mil. shares @ $7 to $8
Shares Outstanding: 19.68 mil. shares
Underwriters: CIBC World Markets
ING Barings/Prudential Vector Healthcare
Company Counsel: Cooley Godward LLP
Manager Counsel: McDermott Will & Emery
Auditor: Ernst & Young LLP
The company has developed a method of directly measuring the impact of genetic mutations on drug resistance and uses this information to guide therapy.
Biotech Growth S.A.
Zesiger Capital Group
Capital Management Services Inc.
Invemed Associates Inc.
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 09/01/1998 1 Expansion $100.0
(Data in $ millions)
Total Revenues: $1.1
Net Loss: -17.1